Table 2.
Percentage Reduction in LDL‐C and Lp(a), Based on Response to Therapy Defined as LDL‐C Reduction >35% and Lp(a) Reduction >10%, Stratified by Baseline Plasma Lp(a) Concentration
| Percentage Reduction at Week 12 | Evolocumab 140 mg SC Biweekly | Evolocumab 420 mg SC Monthly | Overall | |||
|---|---|---|---|---|---|---|
| LDL‐C ≤35% | LDL‐C >35% | LDL‐C ≤35% | LDL‐C >35% | LDL‐C ≤35% | LDL‐C >35% | |
| Baseline Lp(a) >10 mg/dL, n | 31 | 440 | 25 | 399 | 56 | 839 |
| Lp(a) ≤10% | 14 (45.2, 29.2–62.2) | 79 (18.0, 14.7–21.8) | 17 (68, 48.4–82.8) | 86 (21.6, 17.8–25.8) | 31 (55.4, 42.4–67.6) | 165 (19.7, 17.1–22.5) |
| Lp(a) >10% | 17 (54.8, 37.8–70.8) | 361 (82.0, 78.2–85.3) | 8 (32, 17.2–51.6) | 313 (78.4, 74.2–82.2) | 25 (44.6, 32.4–57.6) | 674 (80.3, 77.5–82.9) |
| Baseline Lp(a) >30 mg/dL, n | 21 | 263 | 18 | 239 | 39 | 502 |
| Lp(a) ≤10% | 12 (57.1, 36.5–75.5) | 65 (24.7, 19.9–30.3) | 12 (66.7, 43.7–83.7) | 68 (28.5, 23.1–34.5) | 24 (61.5, 45.9–75.1) | 133 (26.5, 22.8–30.5) |
| Lp(a) >10% | 9 (42.9, 24.5–63.5) | 198 (75.3, 69.7–80.1) | 6 (33.3, 16.3–56.3) | 171 (71.5, 65.5–76.9) | 15 (38.5, 24.9–54.1) | 369 (73.5, 69.5–77.2) |
| Baseline Lp(a) >50 mg/dL, n | 20 | 200 | 13 | 192 | 33 | 392 |
| Lp(a) ≤10% | 11 (55.0, 34.2–74.2) | 52 (26.0, 20.4–32.5) | 9 (69.2, 42.4–87.3) | 60 (31.3, 25.1–38.1) | 20 (60.6, 43.7–75.3) | 112 (28.6, 24.3–33.2) |
| Lp(a) >10% | 9 (45.0, 25.8–65.8) | 148 (74.0, 67.5–79.6) | 4 (30.8, 12.7–57.6) | 132 (68.8, 61.9–74.9) | 13 (39.4, 24.7–56.3) | 280 (71.4, 66.8–75.7) |
Data are shown as n (%, 95% CI) except as noted. LDL‐C indicates low‐density lipoprotein cholesterol; Lp(a), lipoprotein(a); SC, subcutaneous.